Makers Laboratories deploys Rs 8.4823 crore in mutual funds
Key highlights
- Makers Laboratories made net mutual-fund purchases of Rs 8.4823 crore in Apr-Sept'26.
- Consolidated current investments rose to Rs 20.4058 crore at September 30, 2026, from Rs 11.574 crore at March 31.
- Net operating cash flow increased to Rs 13.1362 crore in Apr-Sept'26 from Rs 3.1245 crore a year earlier.
- Chemical Manufacturing generated Rs 18.7402 crore of half-year segment profit before tax.
powered by IRIS

Makers Laboratories Limited deployed net Rs 8.4823 crore into mutual funds in Apr-Sept'26, using cash from Rs 13.1362 crore of operating inflow and lifting current investments to Rs 20.4058 crore at September 30, 2026 from Rs 11.574 crore at March 31. Cash and cash equivalents closed at Rs 31.11 lakh.
Know Makers Laboratories inside out
Results, valuation, peers and who's buying, in one view.
How did Makers Laboratories use its operating cash?
Makers Laboratories used Rs 8.4823 crore for net mutual-fund purchases during Apr-Sept'26, the largest identified investing outflow in its consolidated cash-flow statement. The group generated Rs 13.1362 crore of net cash from operating activities after paying Rs 2.8834 crore of income tax, compared with Rs 3.1245 crore of operating cash in Apr-Sept'25.
The mutual-fund deployment exceeded the prior-year period's Rs 2.4855 crore net purchase. Net cash used in investing activities rose to Rs 10.1165 crore in Apr-Sept'26 from Rs 4.4586 crore in Apr-Sept'25, while purchases of property, plant and equipment, capital work-in-progress and intangible assets declined to Rs 1.8751 crore from Rs 2.1099 crore.
The filing records mutual-fund activity as a net purchase, meaning purchases and sales are presented together rather than separately. It also reports a Rs 32.93 lakh profit on sale of mutual funds and a Rs 2.02 lakh mark-to-market, or MTM, gain on mutual funds in operating-profit adjustments for Apr-Sept'26; it does not identify individual schemes, maturities or allocations.
How much did Makers Laboratories' current investments increase?
Makers Laboratories' current investments increased by Rs 8.8318 crore to Rs 20.4058 crore at September 30, 2026, from Rs 11.574 crore at March 31, 2026. The reported balance-sheet increase was Rs 35.95 lakh higher than the Rs 8.4823 crore net mutual-fund purchase in the cash-flow statement, and the filing does not provide a line-by-line reconciliation.
Cash and cash equivalents rose to Rs 31.11 lakh at September 30 from Rs 19.68 lakh at the beginning of the financial year, an increase of Rs 11.43 lakh. The closing cash balance was below the Rs 91.72 lakh reported at the end of Apr-Sept'25, while bank balances other than cash equivalents were Rs 48.41 lakh at September 30, 2026.
Current assets were Rs 102.879 crore at September 30, 2026, up from Rs 86.9487 crore at March 31, 2026. Inventories increased by Rs 5.7132 crore to Rs 50.6539 crore and trade receivables rose by Rs 1.9929 crore to Rs 21.8564 crore, alongside the increase in current investments.
Got a follow-up? Ask IRIS
What supported operating cash generation at Makers Laboratories?
Makers Laboratories generated Rs 16.0196 crore of cash from operations before income tax in Apr-Sept'26, compared with Rs 4.4898 crore in Apr-Sept'25. Consolidated profit before tax rose to Rs 17.8427 crore from Rs 3.2703 crore, while depreciation added back in the cash-flow statement was Rs 2.2866 crore against Rs 2.2528 crore a year earlier.
Working-capital movements reduced operating cash in the latest half year. Inventory absorbed Rs 5.7132 crore and trade receivables absorbed Rs 2.02 crore in Apr-Sept'26, whereas receivables released Rs 2.9703 crore in Apr-Sept'25. Other liabilities contributed Rs 2.9959 crore of cash in the latest period, compared with a Rs 65.50 lakh cash outflow a year earlier.
Chemical Manufacturing reported Rs 18.7402 crore of segment profit before tax for the half year ended September 30, 2026, compared with Rs 4.5039 crore in Apr-Sept'25. Pharmaceutical recorded a Rs 89.75 lakh segment loss before tax, narrower than the Rs 1.2336 crore loss in the corresponding earlier period, while consolidated revenue from operations increased to Rs 90.9817 crore from Rs 69.1755 crore.
Chemical Manufacturing revenue was Rs 68.1541 crore in Apr-Sept'26, up from Rs 43.3897 crore in Apr-Sept'25. Pharmaceutical revenue declined to Rs 24.1852 crore from Rs 26.4085 crore; as the cash-flow statement is consolidated, it does not assign mutual-fund deployment to either reportable segment.
What other financing and liquidity movements occurred?
Makers Laboratories used Rs 2.9055 crore in financing activities in Apr-Sept'26, compared with Rs 2.0084 crore generated from financing activities in Apr-Sept'25. The latest period included Rs 2.0601 crore of non-current borrowing repayment, Rs 62.94 lakh of dividend payments and Rs 24.48 lakh of interest paid.
Short-term borrowings increased by a net Rs 31.78 lakh in Apr-Sept'26, compared with a Rs 3.5611 crore net increase a year earlier. Current borrowings stood at Rs 3.0206 crore at September 30, down from Rs 3.7339 crore at March 31, while no non-current borrowings balance was reported at September 30, against Rs 1.029 crore at March 31.
The group paid Rs 23 lakh of lease principal and Rs 5.90 lakh of lease interest during the half year. Current lease liability was Rs 37.14 lakh at September 30, while non-current lease liability was Rs 81.58 lakh, compared with Rs 35.03 lakh and Rs 1.0079 crore, respectively, at March 31.
The unaudited consolidated results were approved by the board on November 4, 2026, and the statutory auditors issued an unmodified limited-review report. The auditors said the subsidiary's reviewed interim results contributed Rs 68.1541 crore of revenue including other income and Rs 14.1496 crore of profit after tax including other comprehensive income for the half year.
Conclusion
Makers Laboratories directed a substantial part of its Apr-Sept'26 operating cash inflow into mutual funds, with Rs 8.4823 crore of net purchases accounting for most of the Rs 10.1165 crore investing outflow. Current investments reached Rs 20.4058 crore as inventories and receivables also increased, while Chemical Manufacturing generated Rs 18.7402 crore of segment profit before tax.
The next results will show whether the current-investment balance changes after the Rs 8.4823 crore mutual-fund deployment and whether Pharmaceutical continues to narrow its loss. Pharmaceutical's Apr-Sept'26 segment loss before tax was Rs 89.75 lakh, compared with Rs 1.2336 crore in Apr-Sept'25, but the filing gives no segment-level cash deployment detail.


